TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures

News Results demonstrated a difference in the number of patients with brain lesions incurred during TAVR with 68% of unprotected patients experiencing new lesions compared to only 20% of patients for which the embolic deflection device was used. Contributed Author:  Keystone Heart Ltd. Topics:  Neurology